2021 annual financial data
Sutro Biopharma 2021 Operating cash flow growth
Direct answer
Operating cash flow growth was -20.47%.
Operating income was -98,524,000 USD and net income was -105,538,000 USD.
Operating cash flow was -81,679,000 USD.
Get free Sutro Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 61,880,000 USD
- Operating income
- -98,524,000 USD
- Net income
- -105,538,000 USD
- Operating cash flow
- -81,679,000 USD